GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » DexCom Inc (NAS:DXCM) » Definitions » Operating Income

DexCom (DexCom) Operating Income : $652 Mil (TTM As of Mar. 2024)


View and export this data going back to 2005. Start your Free Trial

What is DexCom Operating Income?

DexCom's Operating Income for the three months ended in Mar. 2024 was $101 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Mar. 2024 was $652 Mil.

Operating Margin % is calculated as Operating Income divided by its Revenue. DexCom's Operating Income for the three months ended in Mar. 2024 was $101 Mil. DexCom's Revenue for the three months ended in Mar. 2024 was $921 Mil. Therefore, DexCom's Operating Margin % for the quarter that ended in Mar. 2024 was 10.98%.

DexCom's 5-Year average Growth Rate for Operating Margin % was 0.00% per year.

Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. DexCom's annualized ROC % for the quarter that ended in Mar. 2024 was 21.55%. DexCom's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was 41.26%.


DexCom Operating Income Historical Data

The historical data trend for DexCom's Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

DexCom Operating Income Chart

DexCom Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Operating Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only 142.30 299.50 265.80 391.20 597.70

DexCom Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Operating Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 47.20 128.10 205.50 216.90 101.10

DexCom Operating Income Calculation

Operating Income, is the profit a company earned through operations. All expenses, including cash expenses such as cost of goods sold (COGS), research & development, wages, and non-cash expenses, such as depreciation, depletion and amortization, have been deducted from the sales.

Operating Income for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $652 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


DexCom  (NAS:DXCM) Operating Income Explanation

1. Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

DexCom's annualized ROC % for the quarter that ended in Mar. 2024 is calculated as:

ROC % (Q: Mar. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2023 ) + Invested Capital (Q: Mar. 2024 ))/ count )
=404.4 * ( 1 - -10.49% )/( (2070.3 + 2075.6)/ 2 )
=446.82156/2072.95
=21.55 %

where

Note: The Operating Income data used here is four times the quarterly (Mar. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

DexCom's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2023  Q: Mar. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=548.4/( ( (1184.5 + max(153.3, 0)) + (1176.6 + max(144, 0)) )/ 2 )
=548.4/( ( 1337.8 + 1320.6 )/ 2 )
=548.4/1329.2
=41.26 %

where Working Capital is:

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(973.9 + 559.6 + 154.7) - (1470.1 + 18.4 + 46.4)
=153.3

Working Capital(Q: Mar. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(978.6 + 589.1 + 149.8) - (1509.6 + 16.4 + 47.5)
=144

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

3. Operating Income is also linked to Operating Margin %:

DexCom's Operating Margin % for the quarter that ended in Mar. 2024 is calculated as:

Operating Margin %=Operating Income (Q: Mar. 2024 )/Revenue (Q: Mar. 2024 )
=101.1/921
=10.98 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

4. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Operating Income growth rate using Operating Income per share data.


Be Aware

Compared with a company's EBITDA margin, Operating Margin can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin may decline. Often the Operating Margin declines well before the company's revenue or even profit decline. Therefore, Operating Margin is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia's Operating Margin had already been in decline since 2002, although its earnings per share were still rising. Investors who paid attention to Operating Margin would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


DexCom Operating Income Related Terms

Thank you for viewing the detailed overview of DexCom's Operating Income provided by GuruFocus.com. Please click on the following links to see related term pages.


DexCom (DexCom) Business Description

Address
6340 Sequence Drive, San Diego, CA, USA, 92121
Dexcom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery.
Executives
Sadie Stern officer: Chief Human Resources Officer 6340 SEQUENCE DRIVE, SAN DIEGO CA 92121
Steven R Altman director
Kevin R Sayer director
Jereme M Sylvain officer: SVP, Finance & CAO 6340 SEQUENCE DRIVE, SAN DIEGO X1 92121
Jacob Steven Leach officer: SVP, Research & Development 6340 SEQUENCE DRIVE, SAN DIEGO CA 92121
Nicholas Augustinos director 754 GRAND VIEW AVENUE, SAN FRANCISCO CA 94114
Micheal Jon Brown officer: EVP, Chief Legal Officer 6340 SEQUENCE DR, SAN DIEGO CA 92121
Steven Robert Pacelli officer: Vice President Legal Affairs 5555 OBERLIN DRIVE, SAN DIEGO CA 92121
Girish Naganathan officer: EVP Chief Technology Officer C/O DEXCOM, INC., 6340 SEQUENCE DRIVE, SAN DIEGO CA 92121
Barry J. Regan officer: EVP Operations 1023 CHERRY ROAD, MEMPHIS TN 38117
Bridgette P Heller director TECH DATA CORPORATION, 5350 TECH DATA DRIVE, CLEARWATER FL 33760
Matthew Vincent Dolan officer: * 6340 SEQUENCE DR, SAN DIEGO CA 92121
Rimma Driscoll director C/O ZOETIS INC., 10 SYLVAN WAY, PARSIPPANY NJ 07054
Shelly Ramasamy Selvaraj officer: SVP Information Technology 6340 SEQUENCE DRIVE, SAN DIEGO CA 92121
Paul R Flynn officer: EVP, Global Revenue 6340 SEQUENCE DRIVE, SAN DIEGO CA 92121

DexCom (DexCom) Headlines

From GuruFocus

Q4 2021 Dexcom Inc Earnings Call Transcript

By GuruFocus Research 01-22-2024

Q3 2023 Dexcom Inc Earnings Call Transcript

By GuruFocus Research 01-22-2024

Q3 2022 Dexcom Inc Earnings Call Transcript

By GuruFocus Research 01-22-2024

Dexcom Inc at JPMorgan Healthcare Conference Transcript

By GuruFocus Research 01-22-2024

Q2 2023 Dexcom Inc Earnings Call Transcript

By GuruFocus Research 01-22-2024

Q4 2022 Dexcom Inc Earnings Call Transcript

By GuruFocus Research 01-22-2024

Q2 2022 Dexcom Inc Earnings Call Transcript

By GuruFocus Research 01-22-2024